Orange Book product · Generic (ANDA)
LAMIVUDINE AND ZIDOVUDINE
LAMIVUDINE; ZIDOVUDINE
At a glance
May 05, 2017
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 05, 2017
9 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
LAMIVUDINE; ZIDOVUDINE
Strength
150MG;300MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 077558
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LAMIVUDINE; ZIDOVUDINE
- 2017LAMIVUDINE AND ZIDOVUDINEBrand (NDA)
NDA 022018 · PHARMACARE
- 1997COMBIVIRBrand (NDA)
NDA 020857 · VIIV HLTHCARE
- 2019LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 079079 · PHARMOBEDIENT
- 2018LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 077411 · CIPLA
- 2018LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 090679 · MACLEODS PHARMS LTD
- 2018LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 206375 · EPIC PHARMA LLC
- 2015LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 079124 · HETERO LABS LTD III
- 2015LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 079128 · PHARMOBEDIENT
- 2014LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 204005 · NATCO
- 2014LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 203259 · HETERO LABS LTD V
- 2012LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 202418 · AUROBINDO PHARMA LTD
- 2012LAMIVUDINE AND ZIDOVUDINEGeneric (ANDA)
ANDA 090246 · LUPIN LTD
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
